Pfizer seeks emergency approval for its Covid-19 vaccine in India

 

Pfizer seeks emergency approval for its Covid-19 vaccine in India

Pfizer India has become the first pharmaceutical firm to seek from the Drugs Controller General of India (DCGI) an emergency use authorisation for its Covid-19 vaccine in the country, after its parent company secured such clearance in the UK and Bahrain.

The firm, in its application submitted to the drug regulator, has sought permission to import the vaccine for sale and distribution in the country, besides waiver of clinical trials on Indian population in accordance with the special provisions under the New Drugs and Clinical Trials Rules, 2019, official sources said.

“Pfizer India has submitted an application on December 4 to the DCGI seeking emergency use authorization (EUA) for its COVID-19 vaccine in India,” a source told the Press Trust of India.

The UK on Wednesday became the first country to approve the Pfizer/BioNTech vaccine against Covid-19, with the UK regulator Medicines and Healthcare products Regulatory Agency (MHRA) granting a temporary authorisation for its emergency use.

Bahrain on Friday also announced that it has granted an EUA for the two dose vaccine made by Pfizer and its German partner BioNTech. The pharma company has already applied to the US FDA seeking EUA for the vaccine.